Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.06M | $7.14M | $13.8M | $10.4M | $11.7M | $14.5M | $27.0M | $35.3M | $72.6M |
| Revenue growth | — | 246.4% | 93.4% | -24.7% | 12.6% | 23.6% | 86.5% | 30.8% | 105.8% |
| Operating income | -$16.2M | -$21.7M | -$26.3M | -$52.0M | -$65.6M | -$117M | -$190M | -$210M | -$247M |
| Operating margin | -787.0% | -304.7% | -190.6% | -500.1% | -561.0% | -806.6% | -704.1% | -595.0% | -340.4% |
| Net income | -$16.3M | -$21.8M | -$30.6M | -$51.0M | -$66.8M | -$113M | -$181M | -$169M | -$219M |
| Net margin | -789.3% | -306.1% | -221.8% | -491.0% | -571.2% | -779.3% | -669.7% | -479.2% | -301.7% |
| EPS (diluted) | -$48.81 | -$49.78 | -$2.77 | -$2.66 | -$2.67 | -$3.80 | -$5.08 | -$2.90 | -$3.16 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.42M | -$26.1M | -$28.6M | -$17.8M | -$14.8M | -$86.1M | -$60.6M | -$165M | -$250M |
| Capital expenditures | $1.11M | $1.19M | $1.55M | $1.20M | $2.03M | $19.0M | $2.93M | $1.24M | $2.35M |
| Free cash flow | -$2.53M | -$27.3M | -$30.2M | -$19.0M | -$16.8M | -$105M | -$63.6M | -$166M | -$252M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $67.7M | $0.00 | $0.00 | $0.00 | $439M | $339M | $526M | $880M | $628M |
| Total assets | — | $81.6M | $110M | $161M | $480M | $411M | $595M | $957M | $718M |
| Total liabilities | — | $29.3M | $17.0M | $65.7M | $134M | $140M | $224M | $164M | $108M |
| Long-term debt | — | — | — | $14.5M | $29.9M | $30.3M | $30.7M | — | — |
| Shareholders' equity | -$47.2M | -$69.8M | $93.2M | $95.5M | $346M | $271M | $371M | $793M | $610M |
| Retained earnings | — | -$69.9M | -$101M | -$152M | -$218M | -$331M | -$512M | -$681M | -$900M |
| Shares (wtd avg diluted) | — | 815K | 11.0M | 19.1M | 25.1M | 29.7M | 35.6M | 58.2M | 69.3M |
Every figure is extracted from BICYCLE THERAPEUTICS PLC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.